Remission of Refractory PASH Syndrome Using Ixekizumab and D
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Ixekizumab is a relatively new IL-17 blocking agent recently approved for treatment of psoriasis. A first report of successful treatment of PASH syndrome using ixekizumab and doxycycline in a patient who failed other therapies is presented.

A 37-year-old Caucasian male with a familial history of PASH syndrome presented to the clinic for fatigue, pain and worsening of his cutaneous lesions. At presentation the patient had a 10-year history of vegetative pyoderma gangrenosum (PG), acne fulminans, and Hurley Stage IV hidradenitis suppurativa (HS). His condition was refractory to a 2-month trial of clindamycin and Rifampin PTA therapy, a 4-month trial of adalimumab, and a 5-month trial of ustekinumab. The patient was started on ixekizumab therapy with a 160 mg loading dose, followed by 80 mg maintenance doses every 2 weeks. Doxycycline 100 mg twice daily was started at the same time. 12 weeks after starting these treatments his PG, acne conglobate and HS remitted. The patient reported significant improvement in quality of life with decreased fatigue and pain.

While PASH has historically have been managed with PTA therapy and surgery, these have shown limited success. Biologic agents such as adalimumab, anakinra, and ustekinumab have recently demonstrated safety and efficacy for certain but not all PASH patients. Although recent studies have revealed IL-17 plays a critical role in the pathogenesis of PASH,2 to date, there are no reports regarding efficacy of the IL-17-blocker ixekizumab in PASH syndrome.

FDA approved ixekizumab for treatment of plaque psoriasis and psoriatic arthritis. Compared with other biologic agents such as TNF-blockers, ixekizumab may prove more effective in management of PASH patients due to its IL-17 blocking activity since IL-17 drives several key steps in PASH pathogenesis. These findings may have important implications in future management of PASH patients, especially those who do not respond to PTA therapy, surgical intervention or to other biologic agents.